Cullinan Oncology takes a unique approach to drug development through the prism of modern day portfolio management.
Cullinan was formed to capitalize on the latest scientific breakthroughs by advancing a growing portfolio of innovative, early-stage assets.
- Unique, cost efficient business model upends traditional drug development
- Dynamic portfolio management distributes risk, streamlines development and enhances optionality
- Veteran leadership team of oncology researchers, biopharma executives and experienced entrepreneurs
- Capitalize on recent scientific breakthroughs
- Assets sourced internally through Cullinan dry lab or externally through business, academic and pharma collaborations
- Diversification across platforms, mechanisms and modalities